Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim N Chi

Showing results (71-80 of 234) with videos related to

Pageof 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumorsGerald Batist, Karen A Gelmon, Kim N Chi, et al.
European Urology|February 11, 2014
Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance statusArun A Azad, Bernhard J Eigl, Raya Leibowitz-Amit, et al.
International Journal of Cancer|November 5, 2011
Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of diseaseLuke A Selth, Scott Townley, Joanna L Gillis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancerKim N Chi, Sebastien J Hotte, Evan Y Yu, et al.
European Urology|December 29, 2018
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized TrialDaniel J Khalaf, Katherine Sunderland, Bernhard J Eigl, et al.
Clinical Genitourinary Cancer|August 29, 2017
Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus PrednisoneCharles J Ryan, Thian Kheoh, Jinhui Li, et al.
Lab on a Chip|April 16, 2015
Size and deformability based separation of circulating tumor cells from castrate resistant prostate cancer patients using resettable cell trapsXi Qin, Sunyoung Park, Simon P Duffy, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 31, 2018
A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetateDaniel Joseph Khalaf, Claudia M Avilés, Arun A Azad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM TrialJimmy L Zhao, Karim Fizazi, Fred Saad, et al.
The Prostate|September 2, 2014
A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancerArun A Azad, Raya Leibowitz-Amit, Bernhard J Eigl, et al.
Pageof 24

Showing results (71-80 of 234) with videos related to

Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumorsGerald Batist, Karen A Gelmon, Kim N Chi, et al.
European Urology|February 11, 2014
Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance statusArun A Azad, Bernhard J Eigl, Raya Leibowitz-Amit, et al.
International Journal of Cancer|November 5, 2011
Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of diseaseLuke A Selth, Scott Townley, Joanna L Gillis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancerKim N Chi, Sebastien J Hotte, Evan Y Yu, et al.
European Urology|December 29, 2018
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized TrialDaniel J Khalaf, Katherine Sunderland, Bernhard J Eigl, et al.
Clinical Genitourinary Cancer|August 29, 2017
Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus PrednisoneCharles J Ryan, Thian Kheoh, Jinhui Li, et al.
Lab on a Chip|April 16, 2015
Size and deformability based separation of circulating tumor cells from castrate resistant prostate cancer patients using resettable cell trapsXi Qin, Sunyoung Park, Simon P Duffy, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 31, 2018
A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetateDaniel Joseph Khalaf, Claudia M Avilés, Arun A Azad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM TrialJimmy L Zhao, Karim Fizazi, Fred Saad, et al.
The Prostate|September 2, 2014
A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancerArun A Azad, Raya Leibowitz-Amit, Bernhard J Eigl, et al.
Pageof 24